Abstract
Background Cross-sectional prevalence studies provide benefits to policymakers, epidemiologists, trialists, and the future health of target and general populations. Too few of these studies are performed in hotspots of traditional global health disease burden. This results in a lack of recent, local, accurate prevalence estimates to inform policy, epidemiology, and the design of interventional randomized controlled trials that may be conducted in these regions.
Objective This scoping review aims to establish a novel dataset usable as an observational baseline. The topic being analyzed is the set of characteristics describing recently published prospective cross-sectional prevalence studies in sub-Saharan Africa for humans affected with communicable, maternal, neonatal, and nutritional diseases and conditions.
Methods This scoping review conducted a systematic literature search of PubMed. The search identified publications in the last four years describing completed cross-sectional prevalence studies in sub-Saharan Africa. Title and abstract screening was completed. Data extraction was performed on a random sample of the final dataset.
Results This scoping review identified 868 titles and abstracts through our systematic search. Through our screening process, 394 of these were candidates eligible for inclusion in our dataset. Ultimately, 363 were in the final dataset. Of the 38 studies in the random sample, this scoping review found a large portion of the studies completed with no funding. Malaria was the predominant disease studied, followed by parasitic intestinal infection and malnutrition. Studies with funding were slower, from data collection to submission to a journal, than studies with no funding. Studies that use a national ethical review process tend to take longer than those using hospital or university institutional review boards.
Conclusions Cross-sectional prevalence studies are happening in sub-Saharan Africa for many communicable, maternal, neonatal, and nutritional diseases and conditions. This healthy research ecosystem is filled with variety. A variety of data collection methods, sources of funding, types of study sites, and target populations exist. Many studies are self-funded by the principal investigator. These studies are rarely conducted for the explicit purpose of informing the designs of future randomized trials. Some trends might be observable in the data that point to causal factors for study speed or sample size.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding was provided from The Bill & Melinda Gates Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data used in this scoping review is available at two sources. First, for the full dataset—the 363 open-access publications—, please see the Supplementary Materials for a list of citations. Second, for the coded random sample, 38 publications, see the Supplementary Materials for the detailed data.